Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-10
2009-06-23
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C548S400000, C548S452000
Reexamination Certificate
active
07550499
ABSTRACT:
The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1receptor activity.
REFERENCES:
patent: 3118888 (1964-01-01), Giraldi et al.
patent: 3162644 (1964-12-01), Englisch et al.
patent: 4179563 (1979-12-01), Butler
patent: 4186199 (1980-01-01), Glamkowski et al.
patent: 4435391 (1984-03-01), Sasahara et al.
patent: 4663453 (1987-05-01), Glamkowski et al.
patent: 4840947 (1989-06-01), Glamkowski et al.
patent: 4886822 (1989-12-01), Shibuya et al.
patent: 5500424 (1996-03-01), Nagamine et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5708008 (1998-01-01), Audia et al.
patent: 5886004 (1999-03-01), Audia et al.
patent: 6020357 (2000-02-01), Pinto et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6143764 (2000-11-01), Kubo et al.
patent: 6180675 (2001-01-01), Widdowson et al.
patent: 6187797 (2001-02-01), Pruitt et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6410529 (2002-06-01), Chan et al.
patent: 6586453 (2003-07-01), Dhanoa et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 6656933 (2003-12-01), Hickey
patent: 6825355 (2004-11-01), Das et al.
patent: 6863647 (2005-03-01), Pevarello et al.
patent: 6906063 (2005-06-01), Scarborough et al.
patent: 2002/0077486 (2002-06-01), Scarborough et al.
patent: 2003/0061667 (2003-04-01), Lim et al.
patent: 2003/0065176 (2003-04-01), Kang et al.
patent: 2003/0153568 (2003-08-01), Cusack et al.
patent: 2003/0195232 (2003-10-01), Kawasaki et al.
patent: 2003/0207870 (2003-11-01), Dumas et al.
patent: 2003/0216396 (2003-11-01), Dumas et al.
patent: 2004/0023961 (2004-02-01), Dumas et al.
patent: 2004/0038992 (2004-02-01), Bemis et al.
patent: 2004/0102636 (2004-05-01), Miller et al.
patent: 2004/0209930 (2004-10-01), Carboni et al.
patent: 2004/0259875 (2004-12-01), Yura et al.
patent: 2005/0009815 (2005-01-01), DeVita et al.
patent: 2005/0012254 (2005-01-01), Hsu
patent: 2005/0119304 (2005-06-01), Yura et al.
patent: 2005/0203146 (2005-09-01), Herpin et al.
patent: 2005/0256161 (2005-11-01), Tempest et al.
patent: 2005/0267119 (2005-12-01), Chao et al.
patent: 2006/0173002 (2006-08-01), Sutton et al.
patent: 2006/0293281 (2006-12-01), Qiao et al.
patent: 2006/0293336 (2006-12-01), Sutton et al.
patent: 2006/0293522 (2006-12-01), Sutton
patent: 2007/0004677 (2007-01-01), Chao et al.
patent: 0 028 489 (1981-05-01), None
patent: 0 129 692 (1985-01-01), None
patent: 0 265 734 (1988-05-01), None
patent: 0 286 979 (1988-10-01), None
patent: 0 638 557 (1995-02-01), None
patent: 1 120 409 (2001-08-01), None
patent: 1123918 (2001-08-01), None
patent: 1 402 888 (2004-03-01), None
patent: 1 661 879 (2006-05-01), None
patent: 1 712 242 (2006-10-01), None
patent: 1 342 550 (1962-12-01), None
patent: 56-167649 (1981-12-01), None
patent: 58072562 (1983-04-01), None
patent: 62280847 (1987-12-01), None
patent: 03039740 (1991-02-01), None
patent: 4-319958 (1992-11-01), None
patent: 1995101153 (1995-04-01), None
patent: 2001089412 (2001-04-01), None
patent: WO9617825 (1996-06-01), None
patent: WO 97/29743 (1997-08-01), None
patent: WO98/18430 (1998-05-01), None
patent: WO9818430 (1998-05-01), None
patent: WO 98/37035 (1998-08-01), None
patent: WO 98/57951 (1998-12-01), None
patent: WO 99/31086 (1999-06-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/59506 (2000-10-01), None
patent: WO 00/76495 (2000-12-01), None
patent: WO 00/76970 (2000-12-01), None
patent: WO0123358 (2001-04-01), None
patent: WO 01/40231 (2001-06-01), None
patent: WO 01/47919 (2001-07-01), None
patent: WO0151490 (2001-07-01), None
patent: WO 01/55146 (2001-08-01), None
patent: WO 01/57008 (2001-08-01), None
patent: WO 01/72751 (2001-10-01), None
patent: WO 02/44145 (2002-06-01), None
patent: WO 02/064211 (2002-08-01), None
patent: WO 02/090352 (2002-11-01), None
patent: WO02088090 (2002-11-01), None
patent: WO03007955 (2003-01-01), None
patent: WO 03/014064 (2003-02-01), None
patent: WO03013517 (2003-02-01), None
patent: WO 03/026652 (2003-04-01), None
patent: WO 03/045920 (2003-06-01), None
patent: WO 03/055484 (2003-07-01), None
patent: WO 03/055848 (2003-07-01), None
patent: WO 03/080553 (2003-10-01), None
patent: WO2004/002481 (2004-01-01), None
patent: WO2004002481 (2004-01-01), None
patent: WO 2004/012733 (2004-02-01), None
patent: WO 2004/022529 (2004-03-01), None
patent: WO 2004/046090 (2004-06-01), None
patent: WO 2004/060907 (2004-07-01), None
patent: WO 2004/085433 (2004-10-01), None
patent: WO 2004/110374 (2004-12-01), None
patent: WO 2005/080330 (2005-01-01), None
patent: WO 2005/113511 (2005-01-01), None
patent: WO 2005/037763 (2005-04-01), None
patent: WO 2005/042488 (2005-05-01), None
patent: WO 2005/063293 (2005-07-01), None
patent: WO2005070920 (2005-08-01), None
patent: WO 2006/091963 (2006-08-01), None
Okino, et al., Enantioselective Michael Reaction of Malonates to Nitroolefins Catalyzed by Bifunctional Organocatalysts, J. Am. Chem. Soc., 125, 12672-12673 (2003).
Tasler, et al., Non-competitive Inhibitors of Metabotropic Glutamate Receptor 5 (mGluR5), Bioorganic & Medicinal Chemistry Letters 15, 2876-2880 (2005).
West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 365.
U.S. Appl. No. 11/126,915, filed May 10, 2005, Chao et al.
U.S. Appl. No. 11/038,862, filed Jan. 19, 2005, Herpin et al.
Hamada et al., “The antimicrobial activity and syntheses of carbanilide derivatives,” Yakugaku Zasshi, vol. 96 (5), pp. 663-668, 1976, Abstract only, Journal written in Japanese.
Takeuchi et al., “On the antimicrobial activity and syntheses of carbanilide and salicylanilide derivatives,” Yakugaku Zasshi, vol. 102(11), pp. 1023-1030, 1982.
Abbracchio et al., “Purinoceptors: Are there families of P2X and P2Y Purinoceptors?” Pharmac. Ther. vol. 64, pp. 445-475, 1994.
Abbracchio et al., “Characterization of the UDP-glucose receptor (re-named here the P2Y14receptor) adds diversity to the P2Y receptor family”, Trends in Pharmacological Sciences, vol. 24, No. 2, Feb. 2003.
Baurand et al., “The P2Y1Receptor as a Target for the New Antithrombotic Drugs: A Review of the P2Y1Antagonist MRS-2179”, Cardiovascular Drug Reviews, vol. 21, No. 1, pp. 67-76, 2003.
Boeynaems et al., “Overview of the P2Y Receptors as Therapeutic Targets”, Drug Development Research, vol. 52, pp. 187-189, 2001.
Burnstock et al., “P2 Purinergic Receptors: Modulation of Cell Function and Therapeutic Potential”, The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 3, pp. 862-869, 2000.
Cobern et al., “Some New-p-Chlorophenoxycarbanilides and Their Bacteriostatic Activities”, Notes, Unilever Research Laboratory, Colworth House, Sharnbrook, Bedford, England.
Daniel et al., “Molecular Basis for ADP-induced Platelet Activation”, The Journal of Bilogical Chemistry, vol. 273, No. 4, pp. 2024-2029, 1998.
Fabre et al., “Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice”, Nature Medicine, vol. 5, No. 10, Oct. 1999.
Gramatica et al., “QSAR approach for the selection of congeneric compounds with a similar toxicological mode of action”, Chemosphere, vol. 42, pp. 873-883, 2001.
Gschwend et al., “Specificity in Structure-Based Drug Design: Identification of a Novel, Selective Inhibitor ofPneumocystis cariniiDihydrofolate Reductase”, Proteins: Structure, Function and Genetics, vol. 29, pp. 59-67, 1997.
Hechler et al., “The P2Y1receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel”, British Journal of Haematology, vol. 103, pp. 858-866, 1998.
Janssens et al., “Cloning a
Chao Hannguang J.
Gungor Timur
Qiao Jennifer X.
Tuerdi Huji
Wang Tammy C.
Bristol--Myers Squibb Company
Leeser Erich A
Sun Jing G.
Wilson James O
LandOfFree
Urea antagonists of P2Y 1 receptor useful in the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urea antagonists of P2Y 1 receptor useful in the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urea antagonists of P2Y 1 receptor useful in the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115481